Authors: Amber M. Smith, Jonathan A. McCullers
Categories: Article, Alveolar Macrophage, Influenza Infection, Influenza Virus, Influenza Virus Infection, Respiratory Syncytial Virus
Source: Influenza Pathogenesis and Control - Volume I
Doi: 10.1007/82_2014_394
Influenza is often complicated by bacterial pathogens that colonize the nasopharynx and invade the middle ear and/or lung epithelium. Incidence and pathogenicity of influenza-bacterial coinfections are multifactorial processes that involve various pathogenic virulence factors and host responses with distinct site- and strain-specific differences. Animal models and kinetic models have improved our understanding of how influenza viruses interact with their bacterial co-pathogens and the accompanying immune responses. Data from these models indicate that considerable alterations in epithelial surfaces and aberrant immune responses lead to severe inflammation, a key driver of bacterial acquisition and infection severity following influenza. However, further experimental and analytical studies are essential to determining the full mechanistic spectrum of different viral and bacterial strains and species and to finding new ways to prevent and treat influenza-associated bacterial coinfections. Here, we review recent advances regarding transmission and disease potential of influenza-associated bacterial infections and discuss the current gaps in knowledge.
Pneumonia is a leading cause of death in the United States and worldwide [(Centers for Disease Control Deaths and Mortality); World Health Organization]. Multiple respiratory viruses and bacteria can cause an infection that leads to severe pneumonia, and it is now recognized that a high proportion of community-acquired pneumonia is caused by coinfections. Pathogens including influenza viruses, parainfluenza viruses, respiratory syncytial virus (RSV), human metapneumovirus (HMPV), (pneumococcus), , and group A streptococcus (S. pyogenes, or GAS), and others, alone or in various combinations, cause millions of ambulatory care visits for pneumonia and thousands of deaths each year in the United States. The resulting economic burden is greater than 17 billion dollars (File and Marrie 2010). In addition, otitis media is the leading reason for visits to a pediatrician (2.4 million visits per year) (Centers for Disease Control Deaths and Mortality, Centers for Disease Control Estimated Burden of Acute Otits Externa)], further increasing the health care cost of these pathogens. Although otitis media has classically been considered a bacterial disease, an increasing amount of evidence suggests that viral infections are a common cause and a great deal of acute otitis media (AOM) results from coinfections with two or more pathogens (Heikkinen 2000).
Of the multiple viruses and bacteria that participate in coinfections of the lung and middle ear, one of the most important is the influenza virus. Although influenza is a major public health threat on its own, bacterial coinfections complicating influenza contribute greatly by exacerbating disease severity. Detailed descriptions of fatal cases date as far back as the eighteenth century (Laennec 1923) indicating that viral-bacterial coinfections have been recognized as being prevalent for hundreds of years. Since then, further study has taken place. The most infamous event was during the “Spanish Flu” pandemic in 1918–1919 where more than 95 % of the 50+ million deaths were complicated by a bacterial coinfection (Morens et al. 2008). Although significant improvements regarding health care have been made, new pathogenic strains emerge and complications from bacterial coinfections continue. Approximately 50–70 % of severe or fatal cases in the 1957 H2N2 and 1968 H3N2 pandemics and nearly one-third of those in the 2009 H1N1 pandemic had bacterial complications (Louria et al. 1959; Weinberger et al. 2011). Furthermore, when a bacterial coinfection was identified, mortality was high despite appropriate antibiotic use in the majority of cases (Domínguez-Cherit 2009; Kumar 2009; Jain et al. 2009; Palacios et al. 2009). Today, it is well recognized that bacterial pneumonia complicates disease initiated by respiratory pathogens like influenza viruses.
Pneumococcus remains the most frequently identified bacterial pathogen associated with influenza infections and the most common cause of community-acquired pneumonia (CAP) despite use of the pneumococcal conjugate vaccine (PCV) in children and adults (Nelson et al. 2008). However, over the last decade, S. aureus dominated influenza-associated childhood fatalities in the US and accounted for ~75 % of deaths from bacterial coinfections. S. aureus has likely become a more common cause of fulminant coinfections due to the emergence in some countries of the methicillin-resistant clonotypes USA300 and USA400 (MRSA). It is unclear why these strains are more likely lead to secondary pneumonia with influenza than other circulating strains. There is currently no vaccine for S. aureus. Group A streptococcus only occasionally complicates viral infections (Chaussee et al. 2011) and, when present, falls behind pneumococcus and S. aureus in prevalence.
There is little systematic surveillance of bacterial coinfections during seasonal influenza, but this continued threat to public health has led to increased research on the co-pathogenesis of pneumonia due to influenza viruses and bacterial pathogens [reviewed in (Short et al. 2012a; Bosch et al. 2013; Metzger and Sun 2013; McCullers 2014)]. This research has significantly improved the current state of knowledge of influenza coinfections through the use of animal models and, more recently, through the use of theoretical models. Key questions regarding transmission, invasion, and pathogenicity remain unanswered. Identifying how a bacterial coinfection renders mild influenza infections fatal is key to effectively combating pneumonia and preparing for future influenza pandemics.
During the 1918 influenza pandemic, the armed forces of several countries made detailed accounts of infectious disease-related illnesses since their efforts during World War I were severely impacted (Brundage and Shanks 2007; Shanks et al. 2010). This led to the first animal studies confirming that bacteria contribute to disease during influenza virus infections by using filtered and unfiltered human sputum (Wherry and Butterfield 1921). These experiments were followed in 1931 by Shope, who conducted controlled experiments in pigs with a swine influenza virus and suis (Shope 1931), and in the 1940s by Francis and Torregrosa, who used a mouse model with the mouse-adapted influenza A/Puerto Rico/8/1934 virus together with pneumococcus, S. aureus, or H. influenzae (Francis and de Torregrosa 1945). Since then, a variety of animal models have been used to study coinfections (Fig. 1).Fig. 1Animal models of influenza-associated bacterial coinfections. Several different animal models have been used to study the effect that influenza viruses have on bacterial transmission and colonization and on invasive diseases, such as acute otitis media and pneumonia (Wherry and Butterfield 1921; Shope 1931; Francis and de Torregrosa 1945; Berendt et al. 1975; Rarey et al. 1987; Hajek et al. 1999; Hirano et al. 1999; McCullers and Rehg 2002; Okamoto et al. 2003; Seki et al. 2004; Peltola et al. 2006; Montgomery et al. 2008; Small et al. 2010; Diavatopoulos et al. 2010b; Lee et al. 2010; Jamieson et al. 2010; McCullers et al. 2010; Loving et al. 2010; Iverson et al. 2011; Kudva et al. 2011; Ayala et al. 2011; Chaussee et al. 2011; Short et al. 2011; Mina et al. 2013; McHugh et al. 2013; Redford et al. 2014)
The sequential viral-bacterial mouse model of pneumonia, which we characterized in detail in 2002, remains the most useful and well-defined system for investigating coinfections, particularly given the lack of comprehensive data from natural infections in humans. In the initial model, sublethal doses of PR8 and of a type 2 laboratory strain of pneumococcus (D39) reproducibly caused severe secondary bacterial pneumonia when given intranasally in BALB/c mice (McCullers and Rehg 2002). The influenza virus infection had to precede the bacterial challenge to observe synergistic disease. An interval of 3–14 days between inoculations with the organisms resulted in the most severe disease, and peak severity occurred when pneumococcus was given 7 days postviral infection. Simultaneous administration of the two pathogens had only additive effects on morbidity, rather than the synergistic effects observed during the sequential infection. This model was later improved by engineering pneumococcal strains to express luciferase, which allows for quantitative bioluminescent imaging to track progression of the infection in live mice (McCullers and Bartmess 2003).
Multiple strains of influenza, including the 2009 H1N1 pandemic virus, can prime mice for secondary pneumonia (Wanzeck et al. 2011), but the doses necessary to have comparable results differ in a strain-dependent fashion. In addition, other viruses (e.g., rhinovirus, adenovirus, coronavirus, parainfluenza virus, HMPV, and RSV) have been used within the same model framework (reviewed in (Bosch et al. 2013). A variety of clinical outcomes can be modeled with different pneumococcal strains, including pneumonia with and without bacteremia, sepsis with secondary seeding of organs leading to pneumonia, otitis media, and sinusitis (Peltola et al. 2005; McCullers et al. 2007; Smith et al. 2007). Furthermore, multiple bacterial species can synergize with influenza viruses to cause disease (Fig. 1).
The mouse model for influenza-bacterial coinfections has several limitations. For example, viruses that replicate well in mice are required to produce robust and reproducible effects, a limitation that affects the certainty with which conclusions can be extrapolated to humans. This is mitigated somewhat by using different species of mice, including the C57BL/6 strain, which behaves similarly to the BALB/c strain (Karlstrom et al. 2011), and the DBA/2 strain, which is highly permissive to a variety of human influenza strains (Alymova et al. 2011). In addition, a ferret model can be used to confirm results found using the mouse model or to answer questions about strain-related differences in pathogenesis since ferrets are susceptible to most human viruses and exhibit a disease course similar to humans (Peltola et al. 2006; McCullers et al. 2010).
Chinchillas and weanling ferrets can also be infected with a variety of pneumococcal strains (Hajek et al. 1999; McCullers et al. 2010), although the disease manifestations do not map precisely to the mouse model. There are limited data with other viruses and bacteria in the ferret model, but unpublished experience from our laboratory has shown that S. aureus will not cause respiratory infections in ferrets even when the animals are preinfected with influenza. Another limitation of the mouse model is the poor transmission potential for respiratory viruses or bacteria between mice, thus requiring the use of alternate models such as neonatal mice (Diavatopoulos et al. 2010a) or ferrets (McCullers et al. 2010) for transmission studies.
Early animal models of AOM utilized the chinchilla due to their large and accessible middle ear spaces (Hajek et al. 1999). These studies demonstrated that the greatest incidence of AOM occurred in animals receiving bacteria 4–8 days following influenza (Hajek et al. 1999), similar to the data concerning timing of pneumonia. More recently, juvenile and infant mouse models have been developed so that diseases of young adults and children, respectively, can be mimicked (McCullers et al. 2007; Diavatopoulos et al. 2010a). Similar models are used to investigate the effects that influenza viruses have on bacterial colonization (Tong et al. 2001; Nakamura et al. 2011).
Studying viral-bacterial interactions in animal models has significantly increased our knowledge about the transmission and pathogenicity of coinfections. However, age, gender, weight, and exposure to anesthesia all contribute to susceptibility to infection in animals in these models, so extreme care must be taken in pathogenesis studies to control all these variables. In addition, studies must carefully select pathogen strains, inoculum sizes, and the sequence and timing of infections since all influence the progression of bacterial pneumonia following influenza.
Influenza viruses readily transmit from person to person via small or large respiratory droplets from a sneeze or cough. Successful transmission and infection typically begins 1 day prior to developing symptoms, which can last up to 7 days in adults and 21 days or more in children (World Health Organization Writing Group et al. 2006). While influenza viruses can spread by large droplets up to six feet away, pneumococcal transmission is thought to require close contact of individuals. Recent evidence, however, suggests that this distance can be lengthened if the individual is virus infected. In fact, epidemiological studies found connections between upper respiratory tract (URT) infections, likely of viral origin, and an increase in bacterial transmission and carriage prevalence (Gwaltney et al. 1975; García-Rodríguez and Fresnadillo Martínez 2002; Pettigrew et al. 2008; Murphy et al. 2009; Ansaldi et al. 2012).
Influenza virus’ impact on pneumococcal transmission was recently illustrated in the ferret model where transmission events and recipient acquisition increased while the distance necessary for successful bacterial acquisition decreased (McCullers et al. 2010). Both bacterial titers and disease severity intensified in the contact ferrets. This relationship was further examined in the infant mouse model, where influenza virus replication and nasopharyngeal bacterial growth were deemed essential for pneumococcal transmission between littermates (Diavatopoulos et al. 2010b; Short et al. 2012b).
These outcomes may not be seen with all influenza-pneumococcal pairings since all observed effects were both viral and bacterial strain dependent. For instance, H3N2 influenza viruses enhance pneumococcal sinusitis and AOM and induce bacterial colonization and disease more frequently than H1N1 or influenza B viruses (Peltola et al. 2006; Short et al. 2013b). Similarly, colonization and AOM development were greater with pneumococcal serotype 19F compared to serotype 7F (McCullers et al. 2010).
Although the precise mechanisms responsible for enhancing the transmission profile that influenza viruses provide pneumococci are currently unknown, it is likely due to an increase in pathogen density and frequency of secretion events (e.g., sneezing and coughing) in the infected individual combined with a decrease in immunity and resistance from natural barriers breaking down in the person who is newly exposed.
During an influenza virus infection, the respiratory tract environment is primed for efficient bacterial invasion. Natural physiological barriers are compromised and a heightened state of inflammation is reached. Numerous factors dictate whether an individual develops a mild or serious infection. The time between exposure to the virus and the bacteria and the pathogen strain and inoculum size all influence influenza coinfection pathogenesis. In addition, many of the virulence factors expressed by each viral and bacterial pathogen act in strain-specific and site-specific manners and can favor different outcomes. The extensive, and growing, list of possible mechanisms (Fig. 2) emphasizes the need to understand how each interacts and how to effectively combat the disease.Fig. 2Influenza-bacterial interaction during coinfections. Numerous alterations of the respiratory epithelium and host immune responses occur during influenza virus infection that predisposes a host to coinfection with bacterial pathogens. As influenza virus infects and kills host cells, epithelial surfaces become exposed and permissive to bacterial attachment. Physical barriers (e.g., mucociliary transport) are damaged, pathogen detection is decreased, anti-microbial peptides (AMPs) are downregulated, receptors are upregulated, virus production is enhanced, bacterial transepithelial migration is permitted, and repair mechanisms are lost. Several host responses are also dampened, altered, or removed. Alveolar macrophages, neutrophils, dendritic cells, and NK cells have altered cytokine profiles and become impaired and/or depleted. These changes result in a heightened inflammatory environment with decreased bacterial surveillance and eradication
As an influenza virus infection progresses, respiratory tract damage accumulates and primes the damaged and undamaged areas for bacterial colonization due to disrupted mechanical clearance mechanisms and exposed receptors. Airway damage from overexuberant inflammatory responses and disruption of specific immune responses to viral pathogens leave the airways suitable for invasion by bacterial pathogens (reviewed in Short et al. 2012a; Bosch et al. 2013; Metzger and Sun 2013; McCullers 2014).
The host depends on the mucociliary apparatus in the lung and nasal passages to clear invading pathogens, but viral insults can damage the respiratory epithelium and inhibit this mode of removal (Pittet et al. 2010). Receptors [e.g., plate-activating factor receptor (PAFr) (Cundell et al. 1995; Miller et al. 2007)] permissive to attachment of bacterial invaders become exposed in these inflamed areas, as shown by autopsy studies in humans and in vivo infections in mice (Giles and Shuttleworth 1957; Oseasohn et al. 1959; Herzog et al. 1959; Plotkowski et al. 1986, 1993; Louie et al. 2009). Additional adhesion sites in the lung appear as the viral lesions begin to heal. Pneumococcus, H. influenzae, and S. aureus, in particular, all use bacterial adhesions to bind exposed laminin, type I and IV collagen, and fibrin/fibrinogen deposition in areas of incomplete healing (Fainstein et al. 1980). Injured or differentiating cells also provide new sites on apical receptors [e.g., asialylated glycans or integrins) for both S. aureus and Pseudomonas aeruginosa (reviewed in Puchelle et al. 2006).
This increased attachment within the lung, trachea, and nasopharyngeal surfaces may be mediated, at least in part, by viral neuraminidase (NA) activity (Hirano et al. 1999; Peltola et al. 2005), which facilitates bacterial adherence by exposing host cell receptors and providing decoy receptors when sialylated mucins are disrupted. Some bacteria, like pneumococcus, use their own NAs to access receptors and cleave sialic acids to avoid host defenses and prevent mucociliary clearance, replacing, or complementing antecedent viral infections (Camara et al. 1991).
Although decreased mucociliary transport impacts bacterial access to the middle ear, receptor-mediated mechanisms may not be as relevant in AOM. In neonatal mice infected with influenza virus, bacteria can be seen localizing to inflammatory infiltrates, rather than to the epithelium (Short et al. 2011), suggesting that different mechanisms are driving the enhanced bacterial replication. It has been hypothesized that viral-mediated destruction still has a role, but in the context of nutrient availability rather than receptor upregulation (Short et al. 2011).
The influenza glycoprotein hemagglutinin (HA), which binds sialic acid residues on host cell surfaces and aids viral internalization, has an indirect effect on influenza-pneumococcal synergy within the middle ear (Short et al. 2013b). The HA specificity is sufficient to produce differential viral replication and bacterial localization. Here, H3 viruses have higher replicative ability than H1 viruses, even across various NAs, but the effect is site specific and does not depend on cell tropisms (Short et al. 2013a). It is likely that similar mechanisms dictate each type of infection with both the HA and NA having specific roles, but the interactions remain complex. It does, however, help to explain the differential outcomes that different influenza strains have on pneumococcal coinfection.
Various bacterial species frequently colonize the nasopharynx and reach a balance with the mucosal immune response such that they are not harmful to the host. In this state, bacteria exist in either biofilms or move between intracellular and extracellular states. Most often, colonizing strains remain in the upper airways since movement to the lower respiratory tract is inhibited by physical barriers (e.g., mucociliary mechanisms) and by immune responses (e.g., resident immune cells, complement, and mucosal antibodies). In this manner, the breakdown of physical barriers and disruption of host responses can result in bacteria emerging from biofilms (Marks et al. 2013).
Most invasive infections and pneumonia occur within a short period of time after a new strain is acquired from the environment rather than from a long-term carriage isolate disseminating to other sites in the body. This is likely due to colonizing strains being limited by systemic immunity, such as pathogen-specific serum IgG, which prevents successful invasion of the lower airways but may tolerate carriage [reviewed in (McCullers et al. 2010)]. In the mouse model, bacteria are delivered directly to the lung, which mimics a direct-inhalation scenario. It is unclear whether this scenario is physiologically relevant in humans, or whether some period of colonization of the nasopharynx must occur prior to invasion and dissemination [reviewed in (McCullers 2014)]. The inoculum size and volume, and the length of anesthesia all influence how much bacteria reach the lower airways and thus the disease model being studied. Both the ferret and mouse AOM models, on the other hand, use colonization as a prerequisite for pneumonia or AOM, so a more natural infection for this site can be instigated.
Influenza viruses and live-attenuated influenza vaccines (LAIV) can result in prolonged bacterial colonization and enhanced bacterial replication within the nasopharynx in both mice and ferrets (Peltola et al. 2006; Nakamura et al. 2011; Short et al. 2012b; Mina et al. 2013). This may be mediated by type I interferon responses and bacterial toxins, such as pneumococcal pneumolysin (Nakamura et al. 2011). Nasopharyngeal colonization can result in bacterial migration to the middle ear via the Eustachian tube. In mice AOM models, animals become colonized with pneumococcus within 72 h after inoculation and can experience recurrent episodes when virus infected (McCullers et al. 2007). Of those that developed AOM (~70 %), resolution occurred within 48 h but colonization persisted for nearly 30 days (McCullers et al. 2007). In the chinchilla model, animals infected with influenza virus experience negative middle ear pressure and eardrum inflammation associated with epithelial damage and cellular and mucosal debris accumulation in the Eustachian tube (Giebink et al. 1987). Similarly, both virus-mediated inflammation and hearing loss are observed in neonatal mice and ferrets (Rarey et al. 1987; Short et al. 2011). However, in contrast to the findings in chinchillas, minimal Eustachian tube damage is observed and bacterial localization specificity suggests that invasion techniques observed in other models are unlikely to be relevant to bacterial AOM (Short et al. 2011). Nevertheless, the increased pathology may support bacterial replication in the middle ear.
If bacteria are successful in migrating to the lungs, a combination of increasing bacterial burden and an accompanying, intense inflammatory response may result in the host developing pneumonia. The early stages of pneumonia are marked by capillary congestion and fluid in the alveolar regions, which provides a medium where pneumococci can readily grow [reviewed in (McCullers 2001)]. As blood vessels become permeable, inflammatory cells are allowed to enter the lung, receptors become upregulated and bacteria easily adhere to, invade, and kill epithelial cells. The combined effects result in significant inflammation, a hallmark of pneumonia.
During coinfections, the host is in a relative state of immune dysregulation with heightened inflammatory and anti-inflammatory responses [reviewed in (Short et al. 2012a; Bosch et al. 2013; Metzger and Sun 2013; McCullers 2014)] likely due to expression of various pathogenic factors. Bacterial cytotoxins, like the pneumococcal pneumolysin (Tuomanen et al. 1995; Kadioglu et al. 2008), S. aureus panton-valentine leukocidin (PVL) (Niemann et al. 2012) and B. pertussis toxin (PT) (Ayala et al. 2011), are known to influence host inflammation and may work in concert with viral cytotoxins. These bacterial factors may intensify the cell death and inflammatory signaling resulting from pores formed by the influenza cytotoxic protein, PB1-F2 (Chen et al. 2001).
The PB1-F2 protein of some influenza viruses increases pathologic effects by causing cell death, increasing viral replication, and altering inflammatory responses to primary viral infections and to bacterial coinfections (Conenello et al. 2007; McAuley et al. 2007, 2010a, b; Smith et al. 2011a, 2013). PB1-F2 can act in a proapoptotic fashion due to its mitochondrial targeting sequence and ability to form pores when interacting with membrane-based proteins (Chen et al. 2001; Gibbs et al. 2003; Chanturiya et al. 2004; Zamarin et al. 2005; Danishuddin et al. 2010; McAuley et al. 2010a). This likely results in the death of epithelial cells and immune cells, which may balance the high replicative ability and support rapid spread through cell monolayers thereby contributing to virulence in vivo (Zamarin et al. 2006; McAuley et al. 2010a, b; Smith et al. 2011a; Varga et al. 2011, 2012). Kinetic analyses suggest that this mechanism impacts viral loads during the later stages of the influenza infection, but is overshadowed by more prominent mechanisms during secondary bacterial infections (Smith et al. 2011a, 2013).
These cellular effects have been mapped to a specific set of amino acids in the C-terminal end of the protein, which are found in most of the early twentieth century H1N1 strains (McAuley et al. 2010a). Although rare (Hai et al. 2010), a serine at position 66 (i.e., ‘66S polymorphism’) impacts virulence with highly pathogenic strains with full-length PB1-F2s (e.g., 1918 H1N1, H5N1) but not less pathogenic strains with truncated PB1-F2s (e.g., 2009 H1N1) (Conenello et al. 2007, 2011; Hai et al. 2010; Varga et al. 2011, 2012). The 66S polymorphism facilitates binding of PB1-F2 to the mitochondrial antiviral-signaling (MAVS) protein adaptor protein and subsequent inhibition of interferon production (Varga et al. 2011, 2012). As a result, viral virulence in primary infection and secondary bacterial infection models is severely exacerbated.
The most relevant PB1-F2 mechanism may be its ability to modulate the immune response during influenza infections and coinfections. The high proinflammatory activity of PB1-F2 intensifies disease in animal models, particularly with respect to induction and severity of bacterial coinfections (McAuley et al. 2007, 2010a; Alymova et al. 2011; Weeks-Gorospe et al. 2012), and is marked by a large influx of immune cells and cytokine storm (Conenello et al. 2007; McAuley et al. 2007, 2010a). Pathogenic PB1-F2s, such as that from the 1918 pandemic strain, elevate neutrophils and macrophages and contribute to the pathologic tissue destruction observed during bacterial coinfections (McAuley et al. 2007). This is likely due to regulation of the type I interferon response (le Goffic et al. 2010; Conenello et al. 2011; Varga et al. 2011, 2012) and apoptotic monocytes infected with influenza (Chen et al. 2001; Gibbs et al. 2003; Zamarin et al. 2005). Specific molecular signatures that facilitate this inflammatory environment have been identified (McAuley et al. 2007, 2010b). Amino acids 62L, 75R, 79R, and 82L in the C-terminal portion of PB1-F2 of select strains are positively associated with inflammation and hypercytokinemia in infected animals and negatively correlated with survival. The precise mechanism and contribution of these signatures singly or in combination is unclear.
Pathogenicity of the 1918 H1N1 pandemic strain was likely impacted by possession all four inflammatory signatures together with the 66S polymorphism. While the 1957 H2N2 and 1968 H3N2 pandemic strains also had all four amino acids, both lacked the 66S polymorphism. Subsequent circulating strains became truncated in the H1N1 lineage around 1948 (McAuley et al. 2010a) and mutations in the H3N2 lineage resulted in loss of the inflammatory signatures by the 1980s. In fact, an antibacterial phenotype emerged in the H3N2 lineage such that viruses and invading bacteria compete via PB1-F2 expression rather than synergize (Alymova et al. 2011; Weeks-Gorospe et al. 2012). The expression of these signatures and the length of PB1-F2 proteins vary widely within influenza viruses. In general, viruses with only the 66S signature or a full set of the polymorphisms strongly support bacterial pathogens, while truncation results in an intermediate phenotype (Zell et al. 2007) and a single substitution at position 82 confers anti-inflammatory properties (Weeks-Gorospe et al. 2012). The range of phenotypes highlights the intricate and complicated nature of influenza infections and coinfections and links specific molecular signatures to pathogenicity. It is important to note that each of these effects was demonstrated in animal models using specific viruses [e.g., H3N2 (Alymova et al. 2011), swine H1N1, H1N2, H3N2 (Weeks-Gorospe et al. 2012)]. The H5N1 viruses are of particular interest for further study since they have little diversity in their PB1-F2, are typically full length, and are more likely to possess the full inflammatory panel with the exception of the 66S polymorphism (Smith and McCullers 2013).
A key prerequisite for bacterial invasion into respiratory epithelium is the induction of inflammation. Several immune responses are activated and act to control bacterial pathogens that invade the lung (Joyce et al. 2009; Koppe et al. 2012). A robust initial response is sufficient to immobilize bacterial invaders before full establishment and uncontrolled growth puts the host in a harmful inflammatory state. The degree of attack and the initial replicative ability within mice are dose-dependent and occur in the lung only when alveolar macrophages become overwhelmed with bacteria (Smith et al. 2011b).
For small inocula of bacteria, resident macrophages provide the first line of defense and result in rapid elimination of bacterial pathogens while maintaining homeostasis, which is represented by a low inflammatory state (Knapp et al. 2003; Dockrell et al. 2003 Smith et al. 2003, 2011b). However, given a large invasion or a compromised host state (e.g., influenza virus infected), bacterial outgrowth occurs and an inflammatory response is launched. Neutrophils appear first and are followed shortly by inflammatory macrophages (Jonsson et al. 1985; Fillion et al. 2001; Knapp et al. 2003). The inflammatory influx in the lungs results from bacterial recognition by antigen presenting cells (APCs), and subsequent cytokine and chemokine production. Bacterial phagocytosis by these cells is only efficient if ample complement proteins are available to opsonize the pathogen or if type-specific antibody is made available by B-cells.
Respiratory viruses compromise many aspects of the early detection and response to bacterial pathogens like pneumococcus or S. aureus [reviewed in (Short et al. 2012a; Bosch et al. 2013; Metzger and Sun 2013; McCullers 2014)]. Viruses and bacteria also activate many of the same cytokines, inflammatory cells, and pattern recognition receptors (e.g., TLR4) that can synergize during coinfections and generate inflammation (Navarini et al. 2006; Joyce et al. 2009; Karlstrom et al. 2011; Kuri et al. 2013). Interference of immune responses occurs through various manners, such as by viral expression of multifunctional proteins like the influenza virus NS-1 (Hale et al. 2008) and PB1-F2 (McAuley et al. 2007, 2010a). Depending on the stage of influenza, the innate, cellular, and anergic responses may differentially synergize.
Since phagocytic cells are critical in creating a bactericidal environment, it is not surprising that these cells are impacted by viral and bacterial mechanisms when secondary infections occur. The activity of neutrophils and macrophages is dampened along with their cytokine production as natural killer (NK) cells become impaired during influenza virus infection and undergo additional suppression during coinfections as a result of heightened TNF-α expression (Small et al. 2010). Further functional suppression of these cells occurs when type I interferons (IFN-α,β) place epithelial cells in antiviral states and alter their chemotactic functions (Joyce et al. 2009; Shahangian et al. 2009; le Goffic et al. 2010; Conenello et al. 2011; Nakamura et al. 2011; Tian et al. 2012; Li et al. 2012). For instance, neutrophil chemoattractants KC and MIP-2 (Shahangian et al. 2009) and macrophage chemoattractant CCL2 (Nakamura et al. 2011) all become downregulated, which inhibits recruitment of immune cells leading to inefficient bacterial clearance. IFN-α,β may also decrease Th-17 cytokines IL-17, IL-22, and IL-23 during S. aureus coinfection, which increases inflammation and decreases viral and bacterial clearance (Kudva et al. 2011).
Production of interferon-γ increases during influenza resolution and can downregulate bacterial scavenger receptors (e.g., MARCO) on macrophages leaving phagocytic cells suppressed and cytokine profiles altered (Didierlaurent et al. 2008; Sun and Metzger 2008). Additional proinflammatory [e.g., IL-1β, TNF-α, IL-6, and IL-12 (Seki et al. 2004; Smith et al. 2007; Shahangian et al. 2009; Nakamura et al. 2011; McHugh et al. 2013)] and anti-inflammatory cytokines [e.g., IL-10 (van der Sluijs et al. 2004)] become inflated and further compound downstream events like macrophage and neutrophil recruitment and dendritic cell function during influenza-pneumococcal coinfection (Sun and Metzger 2008; Shahangian et al. 2009; Wu et al. 2011; Nakamura et al. 2011; Kuri et al. 2013). Even viral and bacterial pathogens themselves can induce apoptosis of phagocytic cells (Colamussi et al. 1999; Engelich et al. 2001; Kobayashi et al. 2003, 2010; McNamee and Harmsen 2006), thus leaving the infected areas severely damaged.
Many of these responses require time to activate, thus the susceptibility of a host to bacterial pathogens following influenza virus infection indicates an effect that may be fully realized during viral preinfection. Indeed, novel analyses of coinfection kinetics identified and detailed the dominant mechanism driving influenza-pneumococcal synergy as a direct viral-dependent reduction in bacterial phagocytosis by alveolar macrophages (Smith et al. 2013). We predicted that this phagocytosis is reduced by 85–90 % at day 7 of the influenza virus infection. We later confirmed that this was a major driver of influenza-pneumococcal synergy with a mouse model by labeling and tracking these cells before and during influenza infections (Ghoneim et al. 2013). Our experiments showed that the resident macrophage population declines as influenza progresses, suggesting that influenza virus directly depletes these cells rather than simply reducing their function. Furthermore, bacterial outgrowth correlated to the level of depletion, which offers new insight into why the timing of bacterial infection has a profound impact on disease outcome (Ghoneim et al. 2013).
As the vigorous antiviral inflammatory response begins to subside, a new state of innate immune activation that may alter responsiveness to new pathogenic insults is reached. The lung becomes repopulated with resident alveolar macrophages as recruited macrophages proliferate and differentiate. In an attempt to return the lung to homeostasis, wound-healing processes coordinate an anti-inflammatory response characterized by IL-10 (van der Sluijs et al. 2004; Hussell and Cavanagh 2009) and suppress pathogen recognition systems [reviewed in (Metzger and Sun 2013)].
During the recovery phase, the host becomes immunologically desensitized both locally and systemically (van der Sluijs et al. 2004; Didierlaurent et al. 2008), which can last for several weeks and prolongs the opportunity for bacterial invasion. The degree and length of this suppression is viral strain-dependent (Ludewick et al. 2011), and occurs through diverse mechanisms. For instance, alveolar macrophages with high expression of homeostatic moieties such as CD200R, a regulatory anti-inflammatory ligand (Barclay et al. 2002; Minas and Liversidge 2006; Snelgrove et al. 2008; Jiang-Shieh et al. 2010), become desensitized when expression of CD200 on apoptotic immune cells increases and open the airways to bacterial invasion (Goulding et al. 2011). In conjunction, absence of CD200R in mice inhibits bacterial outgrowth and prevents migration of bacteria to exogenous sites, such as the blood, in influenza-infected mice (Goulding et al. 2011). Elevated glucocorticoid levels also cause sustained immunosuppression, as was demonstrated in a model of Listeria monocytogenes coinfection (Jamieson et al. 2010).
The inflammatory nature of influenza-pneumococcal coinfections extends to middle ear invasions. Middle ear inflammation, regardless of pathogenic origin, is sufficient to induce AOM. Influenza viruses can initiate this inflammation (Abramson et al. 1981, 1982; Short et al. 2013b), cause hearing loss and instigate bacterial growth within the ear cavity in a viral strain-dependent, but cell tropism independent, manner (Short et al. 2013a).
Inflammation in AOM is characterized by an influx of neutrophils and expression of key proinflammatory genes (i.e., pro-IL-1β, IL-1α, and CXCL2) (Abramson et al. 1981, 1982; Short et al. 2011, 2013b). Chinchilla studies indicate that immunosuppression, rather than inflammation, is the key mechanism contributing to enhanced pneumococcal replication since influenza viruses can inhibit neutrophils and render clearance ineffective (Abramson et al. 1981, 1982). However, it has also been hypothesized that the enhanced bacterial growth results from nutrients becoming available in areas damaged by this response (Short et al. 2013b). More experiments are clearly necessary to elucidate the underlying relationship between viral replication and inflammation in AOM.
The mechanisms discussed thus far have detailed how the virus affects host responses to invading bacteria. The relationship is somewhat complementary, however, since rebounds in viral load and reduced viral clearance are consistently observed in animal models (McCullers and Rehg 2002; Iverson et al. 2011; Weeks-Gorospe et al. 2012; Smith et al. 2013). The rapidity of the viral reply suggests a fast-acting mechanism, which may occur through direct interactions of the two pathogens, bacterial interference with antiviral immunity, or virulence factors synergizing (Smith et al. 2013). Kinetic studies suggest that pneumococci directly interact with influenza-infected epithelial cells to cause a sudden release of virus (Smith et al. 2013), but experimental studies have not been crafted to confirm this prediction.
The precise effects of bacterial virulence factors are likely type specific as S. aureus may be capable of cleaving influenza hemaggluttinin to enhance invasion of host cells and thus impact viral load (Tashiro et al. 1987). It is feasible that additional, although unknown, bacterial virulence factors have immune-modulatory effects and could interfere with viral clearance, such as T-cell-mediated infected cell clearance or other innate immune components. Determining if bacterial gene products from various species have similar effects during infection and, if so, how they complement viral factors is an important, but largely unexplored, area. Another interesting area for investigation in animal models is the idea that the respiratory and gastrointestinal microbiome affects the development of antiviral responses to pathogens (Ichinohe et al. 2011; Licciardi et al. 2012; Abt et al. 2012; Wang et al. 2013). Understanding how commensal species influence host immune status may help explain the heterogeneity in responses to pathogenic invasions.
The outcome of influenza virus coinfection is often severe despite appropriate vaccination and treatment. In addition, antiviral and antimicrobial resistance is increasing (Musher et al. 2002; Levy and Marshall 2004; Hayden 2006) and many treatment options have the potential to cause adverse effects on the host (McCullers and English 2008; Karlstrom et al. 2011). With the high prevalence of viral-bacterial coinfections in some situations, discovering treatment options that can prevent or treat both the influenza virus infection and the secondary bacterial infection are of utmost importance.
Several antiviral drugs targeted against various influenza virus components have been or are currently being developed [reviewed in (Hayden 2013)]. Neuraminidase inhibitors (NAIs) are one class of drugs that have become the pillar of influenza treatment in recent years. NAIs act to block virus from budding out of infected cells, thereby preventing the spread of virus to neighboring cells (Moscona 2005).
NAI therapy can prevent secondary bacterial pneumonia in animals infected with influenza. Mice given NAI treatment within 72 h postinfluenza infection or prophylactically experienced improved survival due to delayed development of and progression of pneumonia with NAI treatment, decreased viral loads, and reduced secondary bacterial infections. Treatment in the later stages of influenza virus infection (i.e., 5 days) reduces bacterial invasion without any impact on viral loads, signifying that mechanisms independent of replication inhibition are in play (McCullers 2005). Their action may directly, or indirectly, lessen the effects of viral virulence factors, prevent receptor exposure, reduce use of sialic acids as catabolic substrates, and/or activate immunological components in a viral strain-dependent manner [reviewed in (McCullers 2011)].
Although NAI resistance remains problematic and may be reduced with combination therapy, treatment with multiple NAIs can inhibit antiviral efficacy (Duval et al. 2010). NAIs in combination with antibiotics, on the other hand, can facilitate recovery from influenza and alter the coinfection pathogenesis in infected animals (McCullers 2004). Other antivirals [e.g., peramivir and laninamivir (NAIs), favipiravir (RNA polymerase inhibitor)] that are not yet licensed may provide benefit to coinfected hosts, but these have yet to be tested in animal coinfection models.
It is important to note that NAIs specifically target influenza virus NA and do not inhibit bacterial NAs with clinically relevant doses (Nishikawa et al. 2012). While NAIs may reduce incidence of bacterial pneumonia, and thus antibiotic requirements, NAs derived from invasive or commensal bacteria may antagonize their effectiveness (Nishikawa et al. 2012). Thus, NAI therapy could have differential bacterial-dependent effects as well.
Unlike antivirals, which interrupt disease progression by preventing viral spread, antibiotics work to eliminate pathogens directly. Some antibiotics, however, kill bacteria through mechanisms that can have harmful repercussions. For instance, therapy with cell wall active agents (e.g., ampicillin), the mainstay of treatment of community-acquired pneumonia in children (Bradley et al. 2011), causes significant inflammation and lung injury in animal models (Karlström et al. 2009). The characteristic inflammation in secondary bacterial infections is due to immune cells responding to the release of bacterial components, such as cell wall components, during lysis (Karlstrom et al. 2011). Thus, alternative treatments that eliminate pathogens while preserving host integrity are desirable.
Antibiotics that reduce neutrophil influx or cytokines and thus circumvent the inflammatory tissue damage are beneficial in coinfected animals (Karlstrom et al. 2011; Liu et al. 2013). In particular, protein synthesis inhibitors (e.g., clindamycin) and macrolides (e.g., azithromycin) have anti-inflammatory properties in addition to bactericidal activity, thereby clinically curing mice with influenza-associated pneumococcal pneumonia (Karlström et al. 2009). Nevertheless, antibiotic treatment alone is suboptimal.
Anti-inflammatory agents, such as corticosteroids (e.g., dexamethasone), in conjunction with antibiotic therapy improve beta-lactam-induced immunopathology and mortality in animals with severe pneumonia. However, giving dexamethasone prophylactically during influenza infections negatively impacts adaptive immunity and results in reduced viral clearance (Ghoneim and McCullers 2013). Thus, use of immune-modulatory approaches may be best reserved for severe infections where inflammation is driving poor outcomes but avoided in primary viral infections where detrimental effects on the host response may result. Given the benefit of anti-inflammatory treatment and the importance of inflammation in viral-bacterial coinfections, better success may occur if specific inflammatory pathways or pathogenic factors are targeted [reviewed in (McCullers 2011)].
Vaccination remains fundamental to prevention of influenza and bacterial infections. Data from animal models indicate that vaccinating against influenza viruses effectively circumvents bacterial associated pneumonia (Huber et al. 2010; Chaussee et al. 2011; Mina et al. 2013) but may support colonization and replication in the URT (Mina et al. 2013). An important caveat of current vaccines against influenza viruses is that partial protection of related strains may not be sufficient to alleviate bacterial complications. On the other hand, antibacterial vaccines are important to block the specific bacteria being targeted and to prevent clinically severe influenza infections by reducing the coinfection component.
Vaccinating animals against some bacteria (e.g., pneumococcus, H. influenzae) prevents invasive diseases caused by these pathogens, but protection is limited to vaccine-specific types and efficacy may be lost in influenza virus infected animals (Mina et al. 2013). In addition, vaccines against other coinfecting bacteria, such as S. aureus, are not currently available. Interestingly, vaccination with a live-attenuated B. pertussis vaccine can protect against lethal challenges with influenza virus by controlling cytokine responses that lead to virus-mediated inflammation (Li et al. 2010). Although the vaccine has not yet been approved for use in humans, it is promising and may benefit as a prophylactic agent against infection with influenza viruses.
Unraveling the relationships between pathogen replication and interactions and the resulting airway alterations and inflammation that are driving coinfection host pathology and disease is complicated. Kinetic models are a robust means of analyzing experimental results and explaining biological phenomena without testing every scenario experimentally. They have proven valuable in the identification and characterization of mechanisms driving influenza virus infections, pneumococcal infections, and bacterial coinfection establishment and severity.
A growing body of work modeling in vivo influenza virus infections has improved our knowledge about the viral life cycle, viral control by the host, pathogenic differences in strains, and efficacy of antiviral treatment [reviewed in (Smith and Ribeiro 2010; Beauchemin and Handel 2011; Smith and Perelson 2011)]. These models have characterized the spread of virus during early infection and yielded estimates of strain-specific viral infection and production rates, infected cell life spans, and infectious virus half-life, all of which are not amenable to experimental investigation.
Most of these studies model data from humans or large animals where only nasal wash titers are available and, thus, are restricted to studying nasopharyngeal infections (Baccam et al. 2006; Saenz et al. 2010; Canini and Carrat 2010; Pawelek et al. 2012). A few models, however, take advantage of data collected in the mouse model, including pathogen and immunological measurements, to study invasive lung infections (Handel et al. 2010; Miao et al. 2010; Smith et al. 2011a). Viral load dynamics can be accurately modeled using target-cell limitation (Fig. 3), through undefined mechanisms, as the primary means of viral control while excluding specific immune responses (Baccam et al. 2006; Smith et al. 2011a). It is important to note that these models do not discount the fact that immunological factors may drive influenza virus pathogenesis, but that this information can simply not be extracted from viral loads (Smith et al. 2010; Miao et al. 2011). Quantifying the effect that host factors have on viral replication has been restricted by the limited amount of data detailing the innate immune responses [reviewed in (Smith and Perelson 2011)]. As more data arise, new quantitative descriptions of influenza virus kinetics will be developed and will undoubtedly aid experimental interpretation.Fig. 3Kinetics of influenza-pneumococcal coinfection. Model schematic and equations that result in the observed kinetics of influenza virus infection followed by pneumococcus given 7 days postinfluenza infection (Smith et al. 2013). During primary influenza, susceptible epithelial (target) cells (T) become infected at a rate βV per cell. Infected cells (I
1) first undergo an eclipse phase at rate k per cell prior to entering a state (I
2) in which virus is produced. Productively infected cells are lost, through apoptosis, viral cytopathic effects, or removal by immune cells, at a rate δ per cell. Virus (V) is produced at rate p per cell, which is significantly increased by bacterial presence (aP
^z^) (boxed), and cleared at rate c. Invading pneumococci (P) proliferate at maximum rate r with a tissue capacity K
p CFU/ml. Bacteria are cleared via phagocytosis by alveolar macrophages (MA) at rate γf per cell, which is significantly reduced by virus presence \documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$
\left( {\phi V/(K_{PV} + V)} \right)